微信直播

AME医学评论新书《心血管热点问题与专家解析》译者招募

Published at: 2015年第1卷第S1期

关键词:

世界范围内,当今的心血管领域正在掀起一场创新和发展的浪潮。同时,它也面临着诸多问题与挑战。为此,我们力邀来自美国、意大利、德国、法国、韩国、日本、中国等10余个国家的50多位心血管领域著名专家学者针对近两年在国际顶尖期刊上发表的大型临床试验、荟萃分析以及基础研究进行深度解析,共同编写Key Leaders' Opinion on Hot Issues of Cardiovasology.

该书由来自哈尔滨医科大学附属第一医院的刘越医生担任主编,围绕心血管领域热点问题,阐述了生物可吸收性药物洗脱支架的兴起与进展;房颤抗栓方案从药物到左心耳封闭术的不断完善;左室辅助装置在冠脉介入围术期的应用以及甲状腺功能改变在冠心病及其诊疗中影响的新认识等话题,亦阐明了冠脉支架内再狭窄的机制;临界病变、左主干病变和多支病变等冠脉疾病的评估与最优化的血运重建策略;抗凝在肺动脉高压中是否真正有效以及他汀类药物是否适用于心力衰竭的治疗等心血管领域的困惑,不仅有助于我们更好理解心血管病学的发展、紧跟其步伐,促使我们更好将其转化于临床实践造福患者,更有助于我们在创新的道路上不断探索与前行。

AME将同步发行本书的中文版《心血管热点问题与专家解析》,现诚邀国内外该领域优秀医学工作者参与本书的翻译工作!

此专题待翻译文章目录如下,欢迎各位认领:

1. Clinical perspective of optical coherence tomography and intravascular ultrasound in STEMI patients

2. Aspiration thrombectomy in 2015: a TOTAL defeat?

3. When clinical experiences clashes against evidence based medicine: the case of aspiration thrombectomy in primary percutaneous coronary intervention (PCI)

4. Therapeutic hypothermia in ST elevation myocardial infarction (STEMI): a long way to go

5. Therapeutic hypothermia in ST-elevation myocardial infarction (STEMI): targeting the appropriate STEMI

6. Dual antiplatelet therapy duration after drug-eluting stents: how long?

7. Prolonged dual antiplatelet therapy in renal failure: a challenging trade-off

8. Time for science to catch up with clinical practice?

9. Bioresorbable drug eluting scaffolds—are bioresorbable stents ready for today’s clinical practice?

10. Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?

11. Bioresorbable vascular scaffolds—time to vanish?

12. Overlapping meta-analyses of bioresorbable vascular scaffolds versus everolimus-eluting stents: bringing clarity or confusion?

13. Bioresorbable vascular scaffolds—what does the future bring?

14. Bioresorbable scaffold—the holy grail of percutaneous coronary intervention: fact or myth?

15. Predictive scores in chronic total occlusions percutaneous recanalization: only fashionable or really useful?

16. Scoring systems for chronic total occlusion percutaneous coronary intervention: if you fail to prepare you are preparing to fail

17. Chronic total improvement in ventricular function and survival

18. The impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcomes

19. Chronic total occlusion: no more meta-analysis, please—a randomized clinical trial is urgently needed

20. Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?

 

21. Five factors and three characteristics of coronary in-stent restenosis

22. Mechanism of in-stent restenosis after second-generation drug-eluting stents (DES): is it different from bare-metal stents and first-generation DES?

23. Use of intravascular ultrasound vs. optical coherence tomography for mechanism and patterns of instent restenosis among bare metal stents and drug eluting stents

24. In-stent restenosis and thrombosis due to metal hypersensitivity: implications for Kounis syndrome

25. Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm

26. Treatment of coronary in-stent restenosis—evidence for universal recommendation?

27. Treatment for in-stent restenosis: patient-specific decision rather than universal recommendation

28. In-stent restenosis: local drug delivery with a stent or balloon?

29. Network meta-analyses on in-stent restenosis treatment: dealing with complexity to clarify efficacy and safety

30. Optimal interventional strategy for the treatment of coronary in-stent restenosis

31. The appropriate use of risk scores in the prediction of atrial fibrillation

32. A meta-analysis of left atrial appendage closure for stroke prevention in atrial fibrillation—adding to the debate but elements remain unresolved

33. The case of stroke prevention by left atrial appendage occlusion in patients with atrial fibrillation—can we close the file?

34. Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the longterm?

35. Five years of keeping a watch on the left atrial appendage—how has the WATCHMAN fared?

36. Percutaneous left atrial appendage closure: here to stay

37. High risk percutaneous coronary interventions—significance of left ventricular assist device for clinical practice

38. Percutaneous left ventricular assist device in high risk percutaneous coronary intervention

39. Shedding light on the gray zone

40. The fractional flow reserve gray zone has never been so narrow

41. Very long-term follow-up for left main coronary artery stenting: a missing piece of the jigsaw puzzle

42. Completeness of revascularization in multivessel coronary artery disease

43. To complete, or not to complete, that is the question of revascularization in percutaneous coronary intervention with drug-eluting stents for multivessel disease

44. Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension

45. Registry to evaluate early and long-term disease management in PAH (REVEAL)

46. Anti-coagulation in pulmonary arterial hypertension: the real blood and guts

47. Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flowmediated dilatation go down?

48. Hyperglycemic endothelial dysfunction: does it happen and does it matter?

49. Acute hyperglycemia impairs flow-mediated dilatation through an increase in vascular oxidative stress:winter is coming for excess sugar consumption

50. Wave mice: a new tool in the quest to characterize aortic valvular disease etiologies

51. Aortic regurgitation and heart valve disease in mice

52. Statin therapy for heart failure: to prescribe or not?

53. The use of statins in patients with heart failure: more questions than answers

54. Major adverse cardiovascular and cerebral events in hypothyroid patients undergoing percutaneous coronary intervention

55. Evidence and controversies regarding the screening for subclinical hypothyroidism in patients with cardiovascular disease

认领方法:

  1. 下载译者报名表(http://rlxt.amegroups.cn/#notices/9),填写完毕后发送到:rlxt@amegroups.com

  2. 编辑部会综合选择最匹配的专家参与翻译,并给符合要求的专家注册系统账号和获取稿件等信息;

  3. 每位会员/译者认领的书籍和文章均不得超过3本/3篇,编辑部将会对超出译者做出适当的调整;

  4. 注:凡是通过编辑部审核并注册系统账号的专家,我们将会在系统委员风采上展示您的个人风采(包括姓名,科室和简介)

  • 认领截止日期:本次认领长期有效,直至认领完毕。

  • 认领成功后,请在认领成功后的三周内将翻译稿及个人简介上传到系统;并发送到rlxt@amegroups.com

​凡翻译质量通过审核的译者,可获得:

  1. 每翻译一篇文章,即可获得价值200元人民币的科研时间积分(200快币),可换购各种图书/杂志,免费登录视频数据库ASVIDE,观看手术视频(积分限免)。

  2. 译者署名权。

  3. 中文版出版后,获赠新书一本。

主编风采:

刘越,医学博士,博士后,副主任医师/副教授,硕士研究生导师

现工作于哈尔滨医科大学附属第一医院心内科。先后被聘为哈尔滨医科大学附属第一医院国家临床重点专科——心内科学科骨干教师,住院医师规范化培训指导教师,大学生创新指导教师。AME学术沙龙委员和组长,黑龙江省医师协会高血压专业委员会委员,中国中西医结合学会微循环专业委员会青年委员,美国心脏病学会会员,丁香医生审稿专家委员会委员Journal of Thoracic Disease编委,中国胸心血管外科临床杂志和临床与病理杂志的中青年编委,Cardiovascular Diagnosis and Therapy的专题编辑,Alcoholism:Clinical and Experimental Research,Clinical and Experimental Pharmacology and Physiology,Journal of Cardiovascular Pharmacology,Cardiovascular Diagnosis and Therapy,Journal of Thoracic Disease和《临床与病理杂志》等杂志审稿人。科研方向为从事小分子活性肽与心血管疾病防治的研究和冠心病的基础和临床研究。迄今,主持和参与的课题12项。获省厅级科技奖项5项。在国内外核心期刊发表学术论文40余篇,其中SCI收录10篇,国际性学术会议上发表会议论文15篇,参编研究生教材《心血管生理学基础与临床》(第二版)、译著《全动脉化冠状动脉旁路移植术》和《姑息医学的艺术与科学》。

AME医学评论系列图书

AME推出的本系列图书,针对某一话题邀请来自不同国家、不同专业的意见领袖发表观点和声音,百家争鸣,百花齐放。而后将其进行归类和合并及出版,希望能够带给更多临床一线医生一份思考,进而帮助到更多患者。

comments powered by Disqus

附件